Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oxford BioMedica Combines With Mayo Clinic On Gene Therapy For Glaucoma

This article was originally published in The Pink Sheet Daily

Executive Summary

Oxford BioMedica and U.S. researchers at the Mayo Clinic are to use the company's lentivirus vector to deliver two prostaglandin-related genes into the front of the eye to alleviate glaucoma.
Advertisement

Related Content

Amsterdam Molecular Therapeutics Ends Glybera Development, Halves Workforce
Imagen's Ophthalmology In-Licensing Strategy Attracts $40M Series A
Belgium's Amakem Raises €18 million In Europe's Largest Series A So Far In 2011
With 100% Alcon Ownership, Novartis Forms New Eye Care Unit
Sanofi Trades In Phase III TroVax For Early-Stage Ophthalmology Deal
Sanofi Trades In Phase III TroVax For Early-Stage Ophthalmology Deal

Topics

Advertisement
UsernamePublicRestriction

Register

PS072967

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel